Prakiraan pendapatan perusahaan Syros Pharmaceuticals Inc. (SYRS)

Syros - logo grafis emiten SYRS

Syros Pharmaceuticals management is skillfully developing gene technologies to combat cancer, leveraging a product cycle that remains independent of macroeconomic trends. The company's future trading volume demonstrates the result of this strategy, with the current value recorded at 0.00. However, geopolitical risks that limit international testing and patent protection continue to impact the final outcome.

Volume dodolan mangsa ngarep perusahaan: Syros Pharmaceuticals, Inc (SYRS) kanggo 04.07.2022 - 29.03.2025

Rincian metrik lan analitis perusahaan Syros (SYRS)

Analisis kabeh metrik perusahaan:syros.com SYRS
Produk merek Syros Pharmaceuticals Inc.

It is essential for investors to protect capital from market volatility during periods of uncertainty. The current restructuring of the R&D pipeline at Syros Pharmaceuticals (SYRS) and strict resource austerity underscore the critical importance of future revenues. This metric assesses the resilience of expected cash flows, filtering out random market fluctuations. By analyzing the company's projected sales levels, one can determine the commercialization potential of the single remaining molecule. This allows for an assessment of the risk of asset freezing in the event of a potential cooling of demand.

Analisis perusahaan pesaing

Volume dodolan mangsa ngarep perusahaan TEM (Tempus AI)|Dodolan mangsa ngarep perusahaan Qiagen Group|Prakiraan pendapatan perusahaan Ionis Pharma IONS|RGEN - Volume dodolan mangsa ngarep perusahaan|RNA - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan RARE (Ultragenyx)|Volume dodolan mangsa ngarep perusahaan BEAM|Prakiraan volume dodolan Sarepta Corp|Prakiraan pendapatan perusahaan Twist Bioscience, Inc. (TWST)|Volume dodolan mangsa ngarep perusahaan 10x Genomics TXG|Prakiraan pendapatan perusahaan Intellia Therapeutics NTLA|Prakiraan volume pendapatan perusahaan STOK (Stoke Therapeutics, Inc.)|BLFS - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Wave Pharma|mazetx.com (MAZE) - Prakiraan pendapatan perusahaan|SION - Dodolan mangsa ngarep perusahaan|PRME (Prime Medicine Inc) - Prakiraan volume dodolan|Taysha Gene Therapies, Inc. - Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan QURE|MGTX: Pendapatan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan REGENXBIO RGNX|SLDB: Prakiraan pendapatan perusahaan|OCGN: Volume dodolan mangsa ngarep perusahaan|PACB - Prakiraan volume dodolan|BNTC (Benitec Corp) - Volume dodolan mangsa ngarep perusahaan|Prakiraan dodolan perusahaan Design Corp DSGN|Prakiraan pendapatan perusahaan Rocket Pharmaceuticals|Prakiraan volume dodolan 4D Molecular Therapeutics, Inc.|Prakiraan pendapatan perusahaan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan EDIT (Editas Medicine, Inc.)|Prakiraan volume dodolan Silence Therapeutics Corp SLN|PRQR - Prakiraan pendapatan perusahaan|Dodolan mangsa ngarep perusahaan Codexis Inc CDXS|SGMO: Prakiraan volume dodolan|Prakiraan pendapatan perusahaan NAUT|Prakiraan pendapatan perusahaan metagenomi.co|Prakiraan volume dodolan Precision BioSciences Inc.|Prakiraan volume dodolan GBIO|Boundless Bio, Inc. - Prakiraan pendapatan perusahaan|Prakiraan volume dodolan XCUR (Exicure, Inc.)|Dodolan mangsa ngarep perusahaan Imunon, Inc. (IMNN)|PHIO - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan MBIO (mustangbio.com)|RNAZ: Prakiraan volume dodolan|Prakiraan pendapatan perusahaan BNGO|APDN (Applied DNA Corp) - Prakiraan volume dodolan|BLUE: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan ImmunoPrecise (IPA)|OMGA - Volume dodolan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan Singular Genomics OMIC|Pendapatan mangsa ngarep perusahaan RGLS|Telesis Bio Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan TCON (TRACON Pharmaceuticals Inc.)|UBX: Prakiraan volume dodolan